Drug Database
SY

synth conjugated estrogens (Enjuvia)

✓ Approved

Teva Pharmaceutical Industries Ltd. · ESR1

What is synth conjugated estrogens?

synth conjugated estrogens is a therapeutic agent developed by Teva Pharmaceutical Industries Ltd.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesEnjuvia
CompanyTeva Pharmaceutical Industries Ltd.
Molecular TargetESR1
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

synth conjugated estrogens acts on 1 molecular target:

ESR1estrogen receptor 1 (ER, ESR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

synth conjugated estrogens is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Reproductive system and breast disordersAtrophic vulvovaginitis✓ Approved
Surgical and medical proceduresHormone replacement therapy✓ Approved
Reproductive system and breast disordersMenopausal symptoms✓ Approved

Related Research Articles

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

Hyper-Intense Tumor Peripheral Accumulation of Antibody-Conjugated Iron Oxide Nanoparticles can Enable Breast Cancer Detection by Magnetic Particle Imaging.

Korangath Preethi P, Carlton Hayden H, Wong Theresa T, Healy Sean S et al.

Targeting nanoparticles to cancer cells in vivo remains a challenge for cancer imaging. We assessed nanoparticle distribution after injecting iron oxide nanoparticles conjugated with either a monoclonal anti-HER2 (human epidermal growth factor 2), or a non-specific IgG antibody into a human HER2 overexpressing murine breast cancer model. We used Magnetic Particle Imaging (MPI) and histopathology to assess particle localization at 72 h after injection. MPI detects magnetic moments produced by magnetic particles, and histology enables spatial quantification of nanoparticles. Intratumor iron content measured by MPI correlated with inductively coupled plasma mass spectrometry (ρ = 0.868, p < 0.0001). We detected nanoparticle accumulation in tumors, and organs and tissues associated with inflammation. MPI showed higher uptake of nanoparticles in tumors, regardless of their performance in vitro. Spatial analysis showed that 43 ± 7% of nanoparticles that reached the tumor accumulated in the peripheral quartile of the tumor, with decreasing amounts toward the center. Immunohistochemical analysis showed the nanoparticles were strongly associated with inflammatory immune and stromal cells in the tumor microenvironment. This hyperintense peripheral accumulation, or ring pattern, observed with MPI enabled us to distinguish tumors from general inflammation. Iron oxide nanoparticle-mediated MPI has the potential to detect tumors, providing another powerful diagnostic tool.

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-30

CD9+ B Cells Induce T Follicular Helper Cell Apoptosis to Regulate Germinal Center Regression.

Liao Wenjing W, Song Lijuan L, Xu Meiqian M, Liang Tianhao T et al.

Adenoid hypertrophy (AH) is associated with excessive proliferation of germinal center B (GC-B) cells, yet the mechanisms underlying GC regression and termination remain poorly understood. This study used single-cell RNA sequencing (scRNA-seq) to profile the cellular composition of GC-B cells in AH. A unique subset of GC-B cells expressing CD9 was identified through comprehensive scRNA-seq, flow cytometry, and Mass cytometry (CyToF) analyses, with subsequent studies assessing the roles of CD9 and FOXP1 in GC-B cell differentiation and apoptosis pathways. CD9+ B cells were detected throughout GC-B cell development and were regulated by FOXP1. These cells also exhibited activation of cell death-related pathways, particularly during adenoid development. AH samples showed an increase in T follicular helper (Tfh) cells, accompanied by a reduction in CD9+ B cells. In Cd9 knockout mice, CD9 deficiency led to a significant decrease in serum IgG levels. Further analysis revealed that CD9+ B cells promoted Tfh cell apoptosis via pathways such as ALCAM-CD6. CD9+ B cells may regulate GC-B cell regression by inducing Tfh cell apoptosis, and FOXP1 may play a role in their differentiation. These findings clarify mechanisms of GC degeneration and termination, offering potential targets for AH treatment.

PubMedNational science review2026-08-30

Tetraboron MR framework with ortho-B-π-B pattern enables high-efficiency yellow narrowband OLEDs.

Zhang Shuqi S, Yang Yongliu Y, Cheng Zhangli Z, Zhang Tongyuan T et al.

Multiple resonance (MR) frameworks with ortho-boron-π-boron (B-π-B) patterns are promising alternatives to those with para-B-π-B ones for realizing bathochromic narrowband emission, but such cases have been rarely reported, and suffer from significant synthetic challenges. Here, a novel tetraboron MR framework ICZ4B incorporating an ortho-B-π-B pattern was constructed by using indolo[2,3-c]carbazole as the central building block. The well-defined borylation active sites facilitate an efficient one-shot quadruple borylation. ICZ4B not only exhibits bright yellow emission with a small full width at half maximum of 24 nm, but also achieves an improved reverse intersystem crossing rate of 4.7 × 104 s-1. The non-sensitized device realizes an outstanding external quantum efficiency of 36.5%, representing one of the highest results at long wavelengths. This study not only presents a feasible pathway for realizing MR frameworks with ortho-B-π-B patterns via delicate selection of key precursors, but also offers insights for optimizing synthetic strategies for complex MR frameworks.

PubMedInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2026-08-30

Type 2 Diabetes Reshapes the B-Cell Compartment in Tuberculosis, with Reduction of Transitional B Cells and Expansion of Plasmablasts.

Petrone Linda L, Najafi-Fard Saeid S, Altera Anna Maria Gerarda AMG, Aiello Alessandra A et al.

Type 2 diabetes (T2D) increases the risk of tuberculosis (TB) and TB severity; however, its effects on B-cells in the TB-T2D syndemic are not fully understood. We evaluated by flow cytometry, the distribution of circulating B-cell subsets in patients with TB disease, TB-T2D, subjects with TB infection (TBI), TBI-T2D, healthy controls (HCs), T2D, patients with pulmonary respiratory diseases other than TB (ORDs), and ORD-T2D. Plasma levels of unspecific or PPD-specific IgG and B-cell-related soluble factors were measured by multiplex assays. Total B-cell frequency was similar across groups. TB-T2D patients showed decreased transitional B cells compared to TB, TBI-T2D, HC, and T2D. Transitional B-cell frequency significantly and negatively correlated with HbA1c levels in the TB-T2D group. Moreover, plasmablast frequency was increased in TB-T2D compared to TB, TBI-T2D, and T2D. Unspecific or PPD-specific IgG levels were not modulated by T2D. BAFF levels increased in TB and TB-T2D compared to the other groups, whereas the levels of SDF-1 were decreased in TB and TBI irrespective of T2D, compared to the controls. Overall, T2D reshapes B-cell compartments in TB, reducing potentially anti-inflammatory transitional B-cells and increasing plasmablasts, possibly reinforcing inflammation and impacting B-cell development and humoral immunity in TB-T2D.

PubMedBiochimica et biophysica acta. Molecular basis of disease2026-08-30

Targeting CARM1 impairs DNA damage repair and attenuates B-cell acute lymphoblastic leukemia progression.

Liao Peiyun P, Qiu Yingqi Y, Li Meifang M, Hu Rong R et al.

B-cell acute lymphoblastic leukemia (B-ALL) is a prevalent hematological malignancy, posing difficulties in identifying efficacious treatment strategies for refractory and recurrent patients. Our research revealed that coactivator-associated arginine methyltransferase 1 (CARM1) was highly expressed in B-ALL and associated with unfavorable prognostic outcomes. Down-regulation and inhibition of CARM1 effectively suppressed proliferation and colony formation of B-ALL, while also inducing apoptosis and cell cycle arrest. Mechanistically, inhibition or down-regulation of CARM1 reduced PARP1 level and contributed to double-strand breaks (DSBs) accumulation. Inhibition of CARM1 and PARP1 synergistically supressed B-ALL development. Significantly, the inhibition of CARM1 was found to promote memory differentiation and reduce the exhaustion of CD19-CAR-T cells. Taken together, CARM1 inhibition not only suppressed B-ALL but also enhanced the durability of CAR-T cells against B-ALL, which provides novel insights into the tumor suppression and immune regulation of CARM1 inhibition on cancer therapy.

PubMedACS chemical biology2026-08-30

Democratizing LYTACs-A Modular Click Chemistry Platform for the Rapid Assembly of Lysosome-Targeting Chimeras.

Szijj Peter A PA, Li Sherry S, Gilbert Madeline K MK, Rollock Chloë Wood CW et al.

Lysosome-targeting chimeras (LYTACs) are emerging therapeutics that mediate extracellular targeted protein degradation. Through simultaneous engagement of a target protein of interest and a lysosomal trafficking receptor, these bifunctional molecules can facilitate the degradation of both secreted and cell-surface proteins. The original LYTACs were designed to engage the cation-independent mannose-6-phosphate receptor (CI-M6PR) via complex glycopolymer or glycopolypeptide ligands conjugated to target-specific antibodies. However, the complexity of these ligands has limited the broader adoption of LYTACs as research tools. Here, we describe a simple, rapid, and modular click chemistry platform for the generation of CI-M6PR-binding LYTACs. The approach utilizes only commercially available reagents and standard laboratory equipment and allows for the conversion of virtually any antibody into a LYTAC. This method for "democratizing" LYTAC generation should facilitate the widespread adoption of these tools for biological discovery.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about synth conjugated estrogens